Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciencesFRA:82P -5.31%83 Cash Ratio is 2.06 as of Jun. 2026, which is 25% below its 10-year median of 2.74. GuruFocus rates FRA:82P with a GF Score™ of 83/100 and a GF Value™ of €24.40. The stock has 7 warning signs investors should review. Among 973 Drug Manufacturers companies, Pacira BioSciences ranks better than 78.73% on this metric.
Pacira BioSciences has a Cash Ratio of 2.06. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Pacira BioSciences's Cash Ratio or its related term are showing as below:
FRA:82P'
s Cash Ratio Range Over the Past 10 Years
Min: 1.1 Med: 2.74 Max: 8.41
Current: 2.06
During the past 13 years, Pacira BioSciences's highest Cash Ratio was 8.41. The lowest was 1.10. And the median was 2.74.
FRA:82P's Cash Ratio is ranked better than 78.73% of 973
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs FRA:82P: 2.06
Pacira BioSciences (FRA:82P) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Pacira BioSciences Cash Ratio Related Terms
Pacira BioSciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ALVO, BIOA, COLL: Cash Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (FRA:82P) has a Cash Ratio of 2.06 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Pacira BioSciences and its competitors. This is 25% below median its historical median of 2.74. Over the past decade, Pacira BioSciences' Cash Ratio has ranged from 1.10 to 8.41. According to the industry distribution chart, Pacira BioSciences ranks #207 out of 973 companies in the Drug Manufacturers industry, placing it in the top 21.3%.
Is Pacira BioSciences' Cash Ratio too high?
Pacira BioSciences' current Cash Ratio of 2.06 is 25% below median its 10-year median of 2.74. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 8.41. The Drug Manufacturers industry median Cash Ratio is 0.60. Pacira BioSciences' value of 2.06 is 243.3% above this industry median. Based on the distribution chart, Pacira BioSciences ranks #207 out of 973 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pacira BioSciences has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Cash Ratio compare to ALVO and BIOA?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #207 out of 973 companies for Cash Ratio. This places Pacira BioSciences in the top 21% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.60. Pacira BioSciences' value of 2.06 is 243.3% above this benchmark. Historically, Pacira BioSciences' own Cash Ratio has ranged from 1.10 to 8.41 over the past decade. While the company's 10-year median is 2.74 vs. the industry median of 0.60, Pacira BioSciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 973 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Cash Ratio of 2.06 is 243.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Cash Ratio is 2.06, which is 25% below median its own 10-year median of 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Cash Ratio of 2.06. The stock's GF Value™ is €24.40, compared to a current price of €21.40 — trading 12.3% below its estimated fair value. The current Cash Ratio is 2.06, which is 25% below median its 10-year median of 2.74 and 243.3% above the Drug Manufacturers industry median of 0.60. Pacira BioSciences' overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Cash Ratio is 2.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €21.40 is trading 12.3% below its estimated GF Value™ of €24.40.
Key valuation signals for FRA:82P:
Cash Ratio: 2.06 (25% below median its 10-year median of 2.74)
GF Value™: €24.40 vs. price of €21.40 (12.3% below fair value)
Industry Position: 243.3% above the Drug Manufacturers median (#207 of 973)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
83GF Score
Get the complete analysis for FRA:82P
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
